{"id":"dasabuvir","rwe":[{"pmid":"41570233","year":"2025","title":"Bloodborne infections in dental practice: prevalence of markers and phylogenetic analysis of circulating strains.","finding":"","journal":"Voprosy virusologii","studyType":"Clinical Study"},{"pmid":"41471251","year":"2025","title":"Genetic Characterization of Hepatitis C Virus Among People Who Use Crack Cocaine: A Study Conducted on the Brazilian Amazon Coast.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41084624","year":"2025","title":"Exploring phytochemicals as potential pharmacological inhibitors for NS1 protein of Kyasanur forest disease virus using virtual screening, molecular docking, and molecular simulation approach.","finding":"","journal":"PeerJ","studyType":"Clinical Study"},{"pmid":"29999876","year":"2006","title":"Dasabuvir.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"40638564","year":"2025","title":"Exploration of effective pharmacological inhibitors for NS5 protein through computational approach: A strategy to combat the neglected Kyasanur forest disease virus.","finding":"","journal":"PloS one","studyType":"Clinical Study"}],"tags":[{"label":"Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Protein cereblon","category":"target"},{"label":"CRBN","category":"gene"},{"label":"J05AP09","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic hepatitis C","category":"indication"},{"label":"Abbvie Inc","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":607.516,"date":"","count":194,"signal":"Hyperbilirubinaemia","source":"DrugCentral FAERS","actionTaken":"Reported 194 times (LLR=608)"},{"llr":560.774,"date":"","count":218,"signal":"Jaundice","source":"DrugCentral FAERS","actionTaken":"Reported 218 times (LLR=561)"},{"llr":534.248,"date":"","count":139,"signal":"Hepatocellular carcinoma","source":"DrugCentral FAERS","actionTaken":"Reported 139 times (LLR=534)"},{"llr":468.138,"date":"","count":201,"signal":"Hepatic failure","source":"DrugCentral FAERS","actionTaken":"Reported 201 times (LLR=468)"},{"llr":460.311,"date":"","count":213,"signal":"Ascites","source":"DrugCentral FAERS","actionTaken":"Reported 213 times (LLR=460)"},{"llr":351.342,"date":"","count":167,"signal":"Blood bilirubin increased","source":"DrugCentral FAERS","actionTaken":"Reported 167 times (LLR=351)"},{"llr":286.139,"date":"","count":200,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 200 times (LLR=286)"},{"llr":271.451,"date":"","count":103,"signal":"Hepatic encephalopathy","source":"DrugCentral FAERS","actionTaken":"Reported 103 times (LLR=271)"},{"llr":214.777,"date":"","count":100,"signal":"Hepatic cirrhosis","source":"DrugCentral FAERS","actionTaken":"Reported 100 times (LLR=215)"},{"llr":179.416,"date":"","count":231,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 231 times (LLR=179)"},{"llr":177.575,"date":"","count":247,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 247 times (LLR=178)"},{"llr":134.775,"date":"","count":237,"signal":"Asthenia","source":"DrugCentral FAERS","actionTaken":"Reported 237 times (LLR=135)"},{"llr":102.387,"date":"","count":20,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=102)"},{"llr":90.624,"date":"","count":14,"signal":"Child-Pugh-Turcotte score increased","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=91)"},{"llr":88.484,"date":"","count":29,"signal":"Hepatorenal syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=88)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"AbbVie","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2035-01-02","territory":"US","patentNumber":"10105365"},{"source":"FDA Orange Book via DrugCentral","expires":"2035-01-02","territory":"US","patentNumber":"9333204"},{"source":"FDA Orange Book via DrugCentral","expires":"2035-01-02","territory":"US","patentNumber":"9744170"},{"source":"FDA Orange Book via DrugCentral","expires":"2033-10-18","territory":"US","patentNumber":"10201542"},{"source":"FDA Orange Book via DrugCentral","expires":"2033-10-18","territory":"US","patentNumber":"9629841"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"8466159"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"8492386"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"8680106"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"8685984"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-05-17","territory":"US","patentNumber":"10201541"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-05-17","territory":"US","patentNumber":"10201584"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-04-13","territory":"US","patentNumber":"8691938"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-06-09","territory":"US","patentNumber":"8686026"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-04-10","territory":"US","patentNumber":"8420596"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-04-10","territory":"US","patentNumber":"9044480"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-06-10","territory":"US","patentNumber":"9006387"},{"source":"FDA Orange Book via DrugCentral","expires":"2029-09-10","territory":"US","patentNumber":"8642538"},{"source":"FDA Orange Book via DrugCentral","expires":"2029-05-17","territory":"US","patentNumber":"8188104"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-12-19","territory":"US","patentNumber":"8501238"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-11-09","territory":"US","patentNumber":"9139536"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-09-17","territory":"US","patentNumber":"8501238"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-08-25","territory":"US","patentNumber":"8268349"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-08-25","territory":"US","patentNumber":"8399015"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DASABUVIR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:09:42.512954+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T06:09:42.512851+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:10:12.613392+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T06:09:42.615817+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DASABUVIR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:09:58.023026+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3137312/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:09:58.728643+00:00"}},"allNames":"viekira pak (copackaged)","offLabel":[],"synonyms":["dasabuvir sodium monohydrate","dasabuvir","dasabuvir sodium","exviera","ABT-333"],"timeline":[{"date":"2014-11-20","type":"positive","source":"DrugCentral","milestone":"EMA approval (AbbVie Ltd)"},{"date":"2014-12-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Abbvie Inc)"}],"aiSummary":"Dasabuvir, marketed as Viekira Pak by AbbVie, is a direct-acting antiviral agent used in the treatment of chronic hepatitis C, currently holding a significant market position with a key composition patent expiring in 2028. Its mechanism of action, which involves binding to the NS5B protein to inhibit viral replication, provides a strong therapeutic profile against hepatitis C. However, the drug faces competition from several same-class treatments, including ribavirin, telaprevir, boceprevir, simeprevir, and daclatasvir, some of which have earlier patent expiries and are already off-patent, posing a potential threat to its market share.","approvals":[{"date":"2014-11-20","orphan":false,"company":"AbbVie Ltd","regulator":"EMA"},{"date":"2014-12-19","orphan":false,"company":"ABBVIE INC","regulator":"FDA"}],"brandName":"Viekira Pak (Copackaged)","ecosystem":[{"indication":"Chronic hepatitis C","otherDrugs":[{"name":"boceprevir","slug":"boceprevir","company":"Merck Sharp Dohme"},{"name":"daclatasvir","slug":"daclatasvir","company":"Bristol Myers Squibb"},{"name":"elbasvir","slug":"elbasvir","company":"Merck Sharp Dohme"},{"name":"glecaprevir","slug":"glecaprevir","company":"Abbvie Inc"}],"globalPrevalence":58000000}],"mechanism":{"target":"Protein cereblon","novelty":"Follow-on","targets":[{"gene":"CRBN","source":"DrugCentral","target":"Protein cereblon","protein":"Protein cereblon"}],"moaClass":"Breast Cancer Resistance Protein Inhibitors","modality":"Small Molecule","drugClass":"Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Dasabuvir is a non-nucleoside NS5B palm polymerase inhibitor that binds to the NS5B protein, a key enzyme in the hepatitis C virus replication complex, thereby inhibiting viral RNA synthesis and replication."},"commercial":{"launchDate":"2014","_launchSource":"DrugCentral (FDA 2014-12-19, ABBVIE INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4914","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DASABUVIR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DASABUVIR","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:30:00.312011","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:10:12.613496+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ribavirin","drugSlug":"ribavirin","fdaApproval":"1985-12-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telaprevir","drugSlug":"telaprevir","fdaApproval":"2011-05-23","patentExpiry":"May 30, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"boceprevir","drugSlug":"boceprevir","fdaApproval":"2011-05-13","patentExpiry":"Nov 11, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"simeprevir","drugSlug":"simeprevir","fdaApproval":"2013-11-22","patentExpiry":"Sep 5, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"daclatasvir","drugSlug":"daclatasvir","fdaApproval":"2015-07-24","patentExpiry":"Jun 13, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sofosbuvir","drugSlug":"sofosbuvir","fdaApproval":"2013-12-06","patentExpiry":"Sep 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"elbasvir","drugSlug":"elbasvir","fdaApproval":"2016-01-28","relationship":"same-class"},{"drugName":"grazoprevir","drugSlug":"grazoprevir","fdaApproval":"2016-01-28","relationship":"same-class"},{"drugName":"ledipasvir","drugSlug":"ledipasvir","fdaApproval":"2014-10-10","relationship":"same-class"},{"drugName":"ombitasvir","drugSlug":"ombitasvir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"paritaprevir","drugSlug":"paritaprevir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"ritonavir","drugSlug":"ritonavir","fdaApproval":"1996-03-01","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"velpatasvir","drugSlug":"velpatasvir","fdaApproval":"2016-06-28","relationship":"same-class"}],"genericName":"dasabuvir","indications":{"approved":[{"name":"Chronic hepatitis C","source":"DrugCentral","snomedId":128302006,"regulator":"FDA","usPrevalence":2400000,"globalPrevalence":58000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ribavirin","brandName":"ribavirin","genericName":"ribavirin","approvalYear":"1985","relationship":"same-class"},{"drugId":"telaprevir","brandName":"telaprevir","genericName":"telaprevir","approvalYear":"2011","relationship":"same-class"},{"drugId":"boceprevir","brandName":"boceprevir","genericName":"boceprevir","approvalYear":"2011","relationship":"same-class"},{"drugId":"simeprevir","brandName":"simeprevir","genericName":"simeprevir","approvalYear":"2013","relationship":"same-class"},{"drugId":"daclatasvir","brandName":"daclatasvir","genericName":"daclatasvir","approvalYear":"2015","relationship":"same-class"},{"drugId":"sofosbuvir","brandName":"sofosbuvir","genericName":"sofosbuvir","approvalYear":"2013","relationship":"same-class"},{"drugId":"elbasvir","brandName":"elbasvir","genericName":"elbasvir","approvalYear":"2016","relationship":"same-class"},{"drugId":"grazoprevir","brandName":"grazoprevir","genericName":"grazoprevir","approvalYear":"2016","relationship":"same-class"},{"drugId":"ledipasvir","brandName":"ledipasvir","genericName":"ledipasvir","approvalYear":"2014","relationship":"same-class"},{"drugId":"ombitasvir","brandName":"ombitasvir","genericName":"ombitasvir","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02460133","phase":"PHASE4","title":"Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2015-07-10","conditions":["Hepatitis C Virus"],"enrollment":44,"completionDate":"2025-10"},{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":["Hepatitis C, Chronic"],"enrollment":5,"completionDate":"2018-10-22"},{"nctId":"NCT02219490","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-30","conditions":["Chronic Hepatitis C Virus (HCV) Infection Genotype 1"],"enrollment":1596,"completionDate":"2021-05-13"},{"nctId":"NCT02634008","phase":"PHASE3","title":"Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-06","conditions":["Hepatitis C, Acute"],"enrollment":83,"completionDate":"2021-04-30"},{"nctId":"NCT02167945","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-06-12","conditions":["Chronic Hepatitis C Virus (HCV) Infection Genotype 1"],"enrollment":615,"completionDate":"2021-05-13"},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":["Chronic Hepatitis C Infection"],"enrollment":1128,"completionDate":"2017-06-30"},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":["Chronic Hepatitis C"],"enrollment":1275,"completionDate":"2020-09-02"},{"nctId":"NCT02194998","phase":"PHASE2","title":"Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-09-16","conditions":["HIV Infections","Hepatitis C"],"enrollment":46,"completionDate":"2018-11-13"},{"nctId":"NCT02486406","phase":"PHASE2,PHASE3","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":["Chronic Hepatitis C Infection"],"enrollment":64,"completionDate":"2020-11-19"},{"nctId":"NCT02555943","phase":"PHASE2,PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":["Chronic Hepatitis C Infection","HBV Coinfection","Hepatitis B Reactivation"],"enrollment":23,"completionDate":"2021-08"},{"nctId":"NCT01715415","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":["Chronic Hepatitis C Infection"],"enrollment":395,"completionDate":"2014-10"},{"nctId":"NCT02582632","phase":"PHASE3","title":"A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-24","conditions":["Hepatitis C Infection","Hepatitis C Virus"],"enrollment":166,"completionDate":"2016-12-01"},{"nctId":"NCT01939197","phase":"PHASE2,PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":["Hepatitis C Virus Infection","Human Immunodeficiency Virus Infection","Chronic Hepatitis C","Compensated Cirrhosis and Non-cirrhotics"],"enrollment":318,"completionDate":"2016-10-25"},{"nctId":"NCT02219503","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":["Chronic Hepatitis C Infection","Compensated Cirrhosis"],"enrollment":60,"completionDate":"2015-09"},{"nctId":"NCT01716585","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":["Chronic Hepatitis C Infection"],"enrollment":636,"completionDate":"2014-10"},{"nctId":"NCT01674725","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":["Chronic Hepatitis C Infection"],"enrollment":187,"completionDate":"2014-10"},{"nctId":"NCT01767116","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":["Chronic Hepatitis C Infection"],"enrollment":419,"completionDate":"2014-08"},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":["Chronic Hepatitis C","Hepatitis C Virus","Compensated Cirrhosis"],"enrollment":89,"completionDate":"2015-06"},{"nctId":"NCT01704755","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10","conditions":["Chronic Hepatitis C Infection","Compensated Cirrhosis"],"enrollment":381,"completionDate":"2014-09"},{"nctId":"NCT01833533","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":["Chronic Hepatitis C Infection"],"enrollment":305,"completionDate":"2014-09"},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":["Hepatitis C, Chronic"],"enrollment":300,"completionDate":"2021-08-31"},{"nctId":"NCT02461745","phase":"PHASE4","title":"Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2015-06","conditions":["Hepatitis C, Chronic"],"enrollment":200,"completionDate":"2017-05"},{"nctId":"NCT03201718","phase":"","title":"A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-17","conditions":["Hepatitis C Virus (HCV)"],"enrollment":505,"completionDate":"2019-10-11"},{"nctId":"NCT02609659","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":["Hepatitis C Virus (HCV)"],"enrollment":105,"completionDate":"2016-12-28"},{"nctId":"NCT03002818","phase":"","title":"Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-01","conditions":["Chronic Hepatitis C Virus (HCV)"],"enrollment":41,"completionDate":"2018-04-25"},{"nctId":"NCT02803138","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-07","conditions":["Chronic Hepatitis C"],"enrollment":256,"completionDate":"2018-10-21"},{"nctId":"NCT02615145","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-03","conditions":["Chronic Hepatitis C"],"enrollment":472,"completionDate":"2018-03-26"},{"nctId":"NCT02851069","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-23","conditions":["Chronic Hepatitis C"],"enrollment":66,"completionDate":"2018-08-30"},{"nctId":"NCT02734173","phase":"PHASE4","title":"Pilot HCV Direct Acting Antiviral Therapy and Metabolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2015-07","conditions":["Hepatitis C"],"enrollment":24,"completionDate":"2017-05-31"},{"nctId":"NCT03050905","phase":"PHASE4","title":"Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-06-22","conditions":["HCV Coinfection"],"enrollment":7,"completionDate":"2018-11-28"},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":["Hepatitis C, Chronic"],"enrollment":33808,"completionDate":"2017-12-31"},{"nctId":"NCT02636608","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-27","conditions":["Chronic Hepatitis C"],"enrollment":244,"completionDate":"2018-05-23"},{"nctId":"NCT02874066","phase":"PHASE4","title":"PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-03-13","conditions":["Hepatitis Viruses"],"enrollment":46,"completionDate":"2018-12-25"},{"nctId":"NCT02618928","phase":"","title":"The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-15","conditions":["Chronic Hepatitis C"],"enrollment":735,"completionDate":"2018-03-29"},{"nctId":"NCT02498015","phase":"PHASE4","title":"A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-08","conditions":["Hepatitis C, Chronic"],"enrollment":87,"completionDate":"2019-03"},{"nctId":"NCT02582658","phase":"","title":"Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-06","conditions":["Chronic Hepatitis C"],"enrollment":173,"completionDate":"2017-01-12"},{"nctId":"NCT03965286","phase":"","title":"Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-06-01","conditions":["Antiviral Drug"],"enrollment":80,"completionDate":"2020-07"},{"nctId":"NCT02817594","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-20","conditions":["Chronic Hepatitis C"],"enrollment":51,"completionDate":"2018-03-07"},{"nctId":"NCT02581163","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-07","conditions":["Chronic Hepatitis C, Genotype 1 or 4"],"enrollment":314,"completionDate":"2018-02-12"},{"nctId":"NCT02582671","phase":"","title":"The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-05","conditions":["Chronic Hepatitis C"],"enrollment":101,"completionDate":"2017-11-29"},{"nctId":"NCT02581189","phase":"","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-13","conditions":["Chronic Hepatitis C"],"enrollment":565,"completionDate":"2017-12-20"},{"nctId":"NCT02725866","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-05","conditions":["Chronic Hepatitis C"],"enrollment":216,"completionDate":"2017-10-31"},{"nctId":"NCT03053180","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":["Chronic Hepatitis C"],"enrollment":60,"completionDate":"2017-12-18"},{"nctId":"NCT02807402","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-14","conditions":["Chronic Hepatitis C"],"enrollment":522,"completionDate":"2017-08-04"},{"nctId":"NCT02798315","phase":"","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-25","conditions":["Chronic Hepatitis C"],"enrollment":40,"completionDate":"2017-06-12"},{"nctId":"NCT02669940","phase":"","title":"Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-15","conditions":["Chronic Hepatitis C","Genotype 1"],"enrollment":158,"completionDate":"2017-07-04"},{"nctId":"NCT03710252","phase":"PHASE4","title":"A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study","status":"COMPLETED","sponsor":"American Research Corporation","startDate":"2016-03","conditions":["Chronic Hepatitis C"],"enrollment":100,"completionDate":"2017-09"},{"nctId":"NCT02640547","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":["Chronic Hepatitis C"],"enrollment":394,"completionDate":"2017-03-29"},{"nctId":"NCT02517528","phase":"PHASE3","title":"ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07-20","conditions":["Chronic Hepatitis C Virus (HCV)"],"enrollment":104,"completionDate":"2017-03-16"},{"nctId":"NCT00851890","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":["Chronic Hepatitis C Virus Infection"],"enrollment":30,"completionDate":"2009-07"},{"nctId":"NCT01563536","phase":"PHASE2","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02","conditions":["Chronic Hepatitis C Infection"],"enrollment":12,"completionDate":"2013-06"},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":["Chronic Hepatitis C Infection"],"enrollment":148,"completionDate":"2015-07"},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":["Chronic Hepatitis C Infection"],"enrollment":311,"completionDate":"2015-07"},{"nctId":"NCT01911845","phase":"PHASE2","title":"An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04","conditions":["Chronic Hepatitis C Infection","Chronic Hepatitis C"],"enrollment":38,"completionDate":"2014-09"},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":["Chronic Hepatitis C","Cirrhosis"],"enrollment":237,"completionDate":"2017-10-15"},{"nctId":"NCT03122132","phase":"","title":"Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks","status":"COMPLETED","sponsor":"Hepa C","startDate":"2017-02-20","conditions":["Hepatitis C Infection"],"enrollment":200,"completionDate":"2018-03-01"},{"nctId":"NCT02356562","phase":"PHASE2","title":"A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-02-03","conditions":["Chronic Hepatitis C Infection"],"enrollment":29,"completionDate":"2017-07-07"},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":["Chronic Hepatitis C Infection"],"enrollment":3,"completionDate":"2016-12"},{"nctId":"NCT01773070","phase":"PHASE3","title":"A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2013-06","conditions":["Hepatitis C"],"enrollment":478,"completionDate":"2016-10"},{"nctId":"NCT02487199","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-30","conditions":["Hepatitis C Virus (HCV)"],"enrollment":18,"completionDate":"2016-12-05"},{"nctId":"NCT00696904","phase":"PHASE1","title":"Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2008-06","conditions":["HCV Infection"],"enrollment":133,"completionDate":""},{"nctId":"NCT02207088","phase":"PHASE3","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-23","conditions":["Chronic Hepatitis C","Hepatitis C Virus","Compensated Cirrhosis","Severe Renal Impairment","End-stage Renal Disease"],"enrollment":68,"completionDate":"2016-12-06"},{"nctId":"NCT01782495","phase":"PHASE2","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-25","conditions":["Chronic Hepatitis C Infection"],"enrollment":129,"completionDate":"2017-07-13"},{"nctId":"NCT02493855","phase":"PHASE2","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":["Chronic Hepatitis C","Hepatitis C (HCV)","Hepatitis C Genotype 1a"],"enrollment":46,"completionDate":"2016-12"},{"nctId":"NCT02517515","phase":"PHASE3","title":"ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07","conditions":["Hepatitis C Virus (HCV)"],"enrollment":650,"completionDate":"2017-06"},{"nctId":"NCT02442284","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-05-13","conditions":["Chronic Hepatitis C","Cirrhosis","Hepatitis C Virus"],"enrollment":99,"completionDate":"2016-10-31"},{"nctId":"NCT02476617","phase":"PHASE3","title":"Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":["Chronic Hepatitis C","Hepatitis C (HCV)","Hepatitis C Genotype 1a"],"enrollment":25,"completionDate":"2016-12"},{"nctId":"NCT02442271","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-27","conditions":["Chronic Hepatitis C Infection"],"enrollment":222,"completionDate":"2016-09-26"},{"nctId":"NCT02219477","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-24","conditions":["Chronic Hepatitis C","Decompensated Cirrhosis","Hepatitis C Virus"],"enrollment":36,"completionDate":"2017-03-03"},{"nctId":"NCT03149289","phase":"","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","status":"COMPLETED","sponsor":"Società Italiana Talassemie ed Emoglobinopatie","startDate":"2015-03-01","conditions":["Hepatitis C, Chronic","Hemoglobinopathies"],"enrollment":168,"completionDate":"2017-02-01"},{"nctId":"NCT02399345","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-03","conditions":["Chronic Hepatitis C Virus (HCV Infection Genotype 1)"],"enrollment":10,"completionDate":"2015-11"},{"nctId":"NCT02950870","phase":"PHASE4","title":"Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2016-12","conditions":["Chronic Hepatitis, C Virus"],"enrollment":75,"completionDate":"2019-12"},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":["Hepatitis C, Chronic","Human Immunodeficiency Virus"],"enrollment":1000,"completionDate":"2020-12"},{"nctId":"NCT02216422","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":["Chronic Hepatitis C Virus (HCV) Infection"],"enrollment":36,"completionDate":"2015-12"},{"nctId":"NCT02646111","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors (\"PI\") Failures","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2016-01","conditions":["Hepatitis C"],"enrollment":120,"completionDate":"2019-01"},{"nctId":"NCT02534870","phase":"PHASE1","title":"Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09","conditions":["Healthy Volunteer"],"enrollment":18,"completionDate":"2015-09"},{"nctId":"NCT01464827","phase":"PHASE2","title":"ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":["Chronic Hepatitis C","Hepatitis C (HCV)","Hepatitis C Genotype 1"],"enrollment":580,"completionDate":"2013-09"},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":["Hepatitis C","HCV","Chronic Hepatitis C Infection","Hepatitis C Genotype 1"],"enrollment":74,"completionDate":"2012-01"},{"nctId":"NCT00726882","phase":"PHASE2","title":"A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-08","conditions":["HCV Infection"],"enrollment":35,"completionDate":"2010-05"},{"nctId":"NCT01306617","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-02","conditions":["Chronic Hepatitis C Infection","Hepatitis C","Hepatitis C Virus"],"enrollment":50,"completionDate":"2012-10"},{"nctId":"NCT02052349","phase":"PHASE1","title":"Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":["Relative Bioavailability"],"enrollment":12,"completionDate":"2013-12"},{"nctId":"NCT00919490","phase":"PHASE1","title":"A Study of Single Dose of ABT-333 in Healthy Male Adults","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-06","conditions":["HCV Infections"],"enrollment":39,"completionDate":""},{"nctId":"NCT00895102","phase":"PHASE1","title":"Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-04","conditions":["HCV Infection"],"enrollment":34,"completionDate":""},{"nctId":"NCT00909636","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-05","conditions":["HCV Infection"],"enrollment":24,"completionDate":""},{"nctId":"NCT00768690","phase":"PHASE1","title":"A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-10","conditions":["HCV Infection"],"enrollment":45,"completionDate":""}],"_emaApprovals":[{"date":"2014-11-20","status":"Authorised","company":"AbbVie Ltd"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"30778","NDDF":"015829","UNII":"DE54EQW8T1","CHEBI":"CHEBI:85182","VANDF":"4034028","INN_ID":"9741","RXNORM":"1597381","UMLSCUI":"C3852512","chemblId":"CHEMBL3137312","ChEMBL_ID":"CHEMBL3137312","KEGG_DRUG":"D10553","DRUGBANK_ID":"DB09183","PUBCHEM_CID":"56640146","SNOMEDCT_US":"714104000","IUPHAR_LIGAND_ID":"11270","SECONDARY_CAS_RN":"1456607-55-8","MESH_SUPPLEMENTAL_RECORD_UI":"C588260"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2014-","companyName":"AbbVie","relationship":"Original Developer"},{"period":"2014","companyName":"AbbVie Ltd","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.7 hours","fractionUnbound":"0.005%","volumeOfDistribution":"2.13 L/kg"},"publicationCount":539,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AP09","allCodes":["J05AP09","J05AP52"]},"biosimilarFilings":[],"originalDeveloper":"Abbvie Inc","recentPublications":[{"date":"2025 Dec 28","pmid":"41570233","title":"Bloodborne infections in dental practice: prevalence of markers and phylogenetic analysis of circulating strains.","journal":"Voprosy virusologii"},{"date":"2025 Dec 17","pmid":"41471251","title":"Genetic Characterization of Hepatitis C Virus Among People Who Use Crack Cocaine: A Study Conducted on the Brazilian Amazon Coast.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2025","pmid":"41084624","title":"Exploring phytochemicals as potential pharmacological inhibitors for NS1 protein of Kyasanur forest disease virus using virtual screening, molecular docking, and molecular simulation approach.","journal":"PeerJ"},{"date":"2006","pmid":"29999876","title":"Dasabuvir.","journal":""},{"date":"2025","pmid":"40638564","title":"Exploration of effective pharmacological inhibitors for NS5 protein through computational approach: A strategy to combat the neglected Kyasanur forest disease virus.","journal":"PloS one"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"2014","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-12-19T00:00:00.000Z","mah":"ABBVIE INC","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8399015","territory":"US","patent_type":null,"expiry_date":"2024-08-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8268349","territory":"US","patent_type":null,"expiry_date":"2024-08-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8501238","territory":"US","patent_type":null,"expiry_date":"2028-09-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9139536","territory":"US","patent_type":null,"expiry_date":"2028-11-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8188104","territory":"US","patent_type":null,"expiry_date":"2029-05-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8642538","territory":"US","patent_type":null,"expiry_date":"2029-09-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9006387","territory":"US","patent_type":null,"expiry_date":"2030-06-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8420596","territory":"US","patent_type":null,"expiry_date":"2031-04-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9044480","territory":"US","patent_type":null,"expiry_date":"2031-04-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8686026","territory":"US","patent_type":null,"expiry_date":"2031-06-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8691938","territory":"US","patent_type":null,"expiry_date":"2032-04-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10201541","territory":"US","patent_type":null,"expiry_date":"2032-05-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10201584","territory":"US","patent_type":null,"expiry_date":"2032-05-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8492386","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8680106","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8685984","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8466159","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10201542","territory":"US","patent_type":null,"expiry_date":"2033-10-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9629841","territory":"US","patent_type":null,"expiry_date":"2033-10-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9744170","territory":"US","patent_type":null,"expiry_date":"2035-01-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10105365","territory":"US","patent_type":null,"expiry_date":"2035-01-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9333204","territory":"US","patent_type":null,"expiry_date":"2035-01-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:10:12.613496+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}